Related posts
Nervous markets await NvidiaThis summary was created by AI, based on 10 opinions in the last 12 months.
Loblaw Companies Ltd has garnered attention as a strong player in the grocery and pharmacy sectors, benefiting from market dynamics and its strategic acquisitions. Experts praise its robust operational execution, particularly with Shoppers Drug Mart, highlighting the company's successful pivot to healthcare services post-COVID. The inflationary environment has imposed challenges but allowed Loblaw to raise prices without significantly harming demand. Although some experts caution about high valuations and suggest waiting for a pullback, most agree on its potential for long-term growth, particularly in a competitive oligopoly with few rivals. Overall, the sentiment remains positive, driven by the company's unique positioning and diversified business model.
Wait for a pullback, given current highs. As Canada's economy softens, more shoppers spend at their discount banners. Shoppers are doing very well in beauty goods as they get out of the low-margin electronics; many provinces are allowing pharmacists to expand their role, which is another tailwind for Shoppers Drug Mart (that Loblaw owns). They are expanding their margins and guiding higher.
Remarkable sprint for a grocer and drugstore, executing well on both. Benefited from discount banners. Higher margins on strong private label portfolio. SDM is doing very well, same-store sales going up, pharmacies expanding scope of service -- increases revenue and foot traffic. Wait for a pullback to enter.
Defensive consumer staple going into economic slowdown. Over half of food banners are in discount, seeing increased traffic. Plus, more people are cooking at home rather than eating out. SDM has great locations, offers Loblaw products; pharmacists expanding roles, and this increases general traffic. Yield is 1.45%.
(Analysts’ price target is $135.40)Loblaw Companies Ltd is a Canadian stock, trading under the symbol L-T on the Toronto Stock Exchange (L-CT). It is usually referred to as TSX:L or L-T
In the last year, 3 stock analysts published opinions about L-T. 1 analyst recommended to BUY the stock. 1 analyst recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Loblaw Companies Ltd.
Loblaw Companies Ltd was recommended as a Top Pick by on . Read the latest stock experts ratings for Loblaw Companies Ltd.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
3 stock analysts on Stockchase covered Loblaw Companies Ltd In the last year. It is a trending stock that is worth watching.
On 2025-04-24, Loblaw Companies Ltd (L-T) stock closed at a price of $215.31.
Has held in remarkably well; considered a defensive name when markets turn volatile with risk of economic slowdown. Traffic gravitated to its discount banners. Pharmacists' roles have expanded at SDM, which also helps drive traffic. Plans to open more pharmacy-based clinics across Canada. Executing very well. Not inexpensive at 22x forward PE, wait for a pullback.